



Patient
perspectives

What long CAR-T
manufacturing
times mean
for patients





“For me, the long manufacturing time meant that I needed bridging therapy. My disease was aggressive so this was a very anxious time for me.”

- Jonathan Clark



Patient Advocate

diagnosed with Mantle Cell Lymphoma in 2014, relapsed in 2017 – alive & in remission thanks to CAR-T cell therapy



How did you experience
the waiting period?





“Bridging therapy kept the disease at bay, but the side effects were disconcerting. It was as if there was an interaction with my anxiety. One night I was utterly convinced I would not wake up the next morning. Scary.”

- Jonathan Clark



Patient Advocate

diagnosed with Mantle Cell Lymphoma in 2014, relapsed in 2017 –alive & in remission thanks to CAR-T cell therapy



How do you think
manufacturing time
impacts outcomes?





“I’m sure faster manufacturing would improve outcomes, if only because would be fitter mentally and physically before their treatment.”




Patient Advocate

diagnosed with Mantle Cell Lymphoma in 2014, relapsed in 2017 –alive & in remission thanks to CAR-T cell therapy

- Jonathan Clark



Manufacturing time
is more than a
process metric.





For patients, it can influence access, quality of life, and the overall success of the therapy.





Let's exchange.

How can we make CAR-T manufacturing faster, more reliable, and patient-centered?

Drop us a note in the comment section below

